title: Current therapeutic strategy for multiple myeloma.
abstract: This is a review regarding the current therapeutic strategies in the management of multiple myeloma. Due to the introduction of several new effective therapeutic agents, multiple myeloma is one of the most active and changing fields in clinical oncology. Multiple myeloma is caused by the expansion of monoclonal plasma cells and secretion of M-protein (immunoglobulins, Bence Jones protein and free light chain). High-dose chemotherapy supported with autologous peripheral blood stem cells is an effective treatment for the disease. However, multiple myelomas are still difficult to cure and require long-term disease control. In recent years, the introduction of novel drugs (bortezomib, lenalidomide and thalidomide) has improved treatment.
authors.affiliation: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. ken-suzuki@mtb.biglobe.ne.jp
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000367:Age Factors; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage; D001842:Bone and Bones / Q000187:drug effects / Q000473:pathology*; D001897:Boronic Acids / Q000008:administration & dosage; D000069286:Bortezomib; D002986:Clinical Trials as Topic; D003404:Creatinine / Q000097:blood; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D000069448:Denosumab; D003907:Dexamethasone / Q000008:administration & dosage; D004164:Diphosphonates / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D007136:Immunoglobulins / Q000378:metabolism; D007668:Kidney / Q000378:metabolism*; D000077269:Lenalidomide; D015470:Leukemia, Myeloid, Acute / Q000139:chemically induced / Q000453:epidemiology; D060046:Maintenance Chemotherapy; D008558:Melphalan / Q000008:administration & dosage / Q000009:adverse effects; D058990:Molecular Targeted Therapy / Q000379:methods*; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000453:epidemiology; D057285:Precision Medicine / Q000379:methods; D011239:Prednisolone / Q000008:administration & dosage; D011719:Pyrazines / Q000008:administration & dosage; D011788:Quality of Life; D012008:Recurrence; D012074:Remission Induction; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D000077211:Zoledronic Acid
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D007093:Imidazoles; D007136:Immunoglobulins; C009823:M-proteins (Myeloma); D011719:Pyrazines; D000069448:Denosumab; D013792:Thalidomide; D000069286:Bortezomib; D000077211:Zoledronic Acid; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011239:Prednisolone; D003404:Creatinine; D000077269:Lenalidomide; D008558:Melphalan